anurajms/meta_analysis huggingface dataset:
MESH terms:
Physical activity programs for promoting bone mineralization and growth in preterm infants
1. Bone Density [physiology]; 2. Bone Diseases, Metabolic [prevention & control]; 3. Calcification, Physiologic [*physiology]; 4. Infant, Premature [growth & development, *physiology]; 5. Motor Activity [*physiology]; 6. Musculoskeletal Manipulations [*methods]; 7. Randomized Controlled Trials as Topic; 8. Weight Gain [physiology];
MESH terms:
Early light reduction for preventing retinopathy of prematurity in very low birth weight infants
1. *Infant, Very Low Birth Weight; 2. *Lighting [adverse effects]; 3. Eye Protective Devices; 4. Infant, Premature; 5. Light [*adverse effects]; 6. Randomized Controlled Trials as Topic; 7. Retinopathy of Prematurity [etiology, *prevention & control];
MESH terms:
Lung lavage for meconium aspiration syndrome in newborn infants
1. Bronchoalveolar Lavage [*methods]; 2. Meconium Aspiration Syndrome [mortality, *therapy]; 3. Pulmonary Surfactants [*therapeutic use]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants
1. Cyclooxygenase Inhibitors [*therapeutic use]; 2. Ductus Arteriosus, Patent [*drug therapy, *surgery]; 3. Indomethacin [therapeutic use]; 4. Infant, Premature; 5. Infant, Very Low Birth Weight; 6. Ligation; 7. Pneumothorax [etiology]; 8. Postoperative Complications; 9. Randomized Controlled Trials as Topic;
MESH terms:
Early trophic feeding versus enteral fasting for very preterm or very low birth weight infants
1. Adaptation, Physiological; 2. Child Development [*physiology]; 3. Enteral Nutrition [adverse effects, *methods]; 4. Enterocolitis, Necrotizing [prevention & control]; 5. Infant Formula; 6. Infant, Premature; 7. Infant, Very Low Birth Weight [growth & development, *physiology]; 8. Milk; 9. Milk, Human; 10. Parenteral Nutrition [adverse effects, methods]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Vasopressin and its analogues for the treatment of refractory hypotension in neonates
1. Hypotension [*drug therapy]; 2. Lypressin [analogs & derivatives, therapeutic use]; 3. Terlipressin; 4. Vasoconstrictor Agents [*therapeutic use]; 5. Vasopressins [*therapeutic use];
MESH terms:
Nasal versus oral route for placing feeding tubes in preterm or low birth weight infants
1. *Infant, Low Birth Weight; 2. *Infant, Premature; 3. Enteral Nutrition [*instrumentation, methods]; 4. Intubation, Gastrointestinal [*methods]; 5. Intubation, Intratracheal [*methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Hydralazine in infants with persistent hypoxemic respiratory failure
1. Antihypertensive Agents [therapeutic use]; 2. Hydralazine [*therapeutic use]; 3. Hypoxia [*drug therapy]; 4. Infant, Premature; 5. Respiratory Insufficiency [*drug therapy]; 6. Vasodilator Agents [*therapeutic use];
MESH terms:
Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis
1. Alemtuzumab [therapeutic use]; 2. Cladribine [therapeutic use]; 3. Daclizumab [therapeutic use]; 4. Dimethyl Fumarate [therapeutic use]; 5. Fingolimod Hydrochloride [therapeutic use]; 6. Glatiramer Acetate [therapeutic use]; 7. Immunologic Factors [therapeutic use]; 8. *Immunosuppressive Agents [therapeutic use]; 9. Interferon beta-1a [therapeutic use]; 10. Interferon beta-1b [therapeutic use]; 11. *Multiple Sclerosis, Relapsing-Remitting [drug therapy]; 12. Natalizumab [therapeutic use]; 13. Network Meta-Analysis; 14. Recurrence;
MESH terms:
Local corticosteroid injection versus placebo for carpal tunnel syndrome
1. *Adrenal Cortex Hormones [adverse effects]; 2. *Carpal Tunnel Syndrome [drug therapy]; 3. Hand; 4. Randomized Controlled Trials as Topic;
MESH terms:
Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1. *Amyotrophic Lateral Sclerosis [complications]; 2. *Botulinum Toxins, Type A [therapeutic use]; 3. Clinical Trials, Phase II as Topic; 4. *Deglutition Disorders [complications, etiology]; 5. Diarrhea [complications]; 6. *Motor Neuron Disease [complications]; 7. Nausea; 8. Randomized Controlled Trials as Topic; 9. Saliva; 10. Scopolamine Derivatives; 11. *Sialorrhea [drug therapy, etiology];
MESH terms:
Topical clonidine for neuropathic pain in adults
1. Analgesics [therapeutic use]; 2. *Chronic Pain [drug therapy]; 3. Clonidine [adverse effects]; 4. *Diabetic Neuropathies [drug therapy]; 5. *Neuralgia [drug therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Ocrelizumab for multiple sclerosis
1. Antibodies, Monoclonal, Humanized; 2. Gadolinium [therapeutic use]; 3. Interferon beta-1a [adverse effects]; 4. *Multiple Sclerosis [drug therapy]; 5. *Multiple Sclerosis, Relapsing-Remitting [drug therapy]; 6. Recurrence;
MESH terms:
Immunoglobulin for multifocal motor neuropathy
1. *Immunoglobulins, Intravenous [therapeutic use]; 2. Plasma Exchange; 3. *Polyneuropathies [drug therapy]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Siponimod for multiple sclerosis
1. *Azetidines; 2. Benzyl Compounds; 3. *Multiple Sclerosis [drug therapy]; 4. *Multiple Sclerosis, Chronic Progressive;
MESH terms:
Rituximab for people with multiple sclerosis
1. Fingolimod Hydrochloride; 2. Glatiramer Acetate; 3. *Multiple Sclerosis [drug therapy]; 4. *Multiple Sclerosis, Chronic Progressive [drug therapy]; 5. Rituximab [adverse effects];
MESH terms:
Memory rehabilitation for people with multiple sclerosis
1. *Activities of Daily Living; 2. Cognition; 3. Memory Disorders [etiology]; 4. *Multiple Sclerosis; 5. Quality of Life;
MESH terms:
Interventions for promoting physical activity in people with neuromuscular disease
1. Bias; 2. *Exercise; 3. Health Promotion [*methods]; 4. Muscle Stretching Exercises; 5. Neuromuscular Diseases [*rehabilitation]; 6. Outcome Assessment, Health Care; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Resistance Training [statistics & numerical data]; 10. Time Factors; 11. Walking [statistics & numerical data];
MESH terms:
GLP‐1 receptor agonists for Parkinson's disease
1. Bias; 2. Double-Blind Method; 3. Exenatide [administration & dosage, adverse effects, *therapeutic use]; 4. Glucagon-Like Peptide-1 Receptor [*agonists]; 5. Hypoglycemic Agents [administration & dosage, therapeutic use]; 6. Parkinson Disease [*drug therapy]; 7. Placebos [administration & dosage]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Self Administration; 11. Single-Blind Method;
MESH terms:
Anti‐epidermal growth factor receptor therapy for glioblastoma in adults
1. Antibodies, Monoclonal [therapeutic use]; 2. Antineoplastic Agents [*therapeutic use]; 3. Antineoplastic Agents, Immunological [therapeutic use]; 4. Brain Neoplasms [*drug therapy, mortality]; 5. Cancer Vaccines [therapeutic use]; 6. Disease Progression; 7. ErbB Receptors [*antagonists & inhibitors]; 8. Glioblastoma [*drug therapy, mortality]; 9. Lymphopenia [etiology]; 10. Neoplasm Recurrence, Local [drug therapy]; 11. Neutropenia [etiology]; 12. Protein Kinase Inhibitors [*therapeutic use]; 13. Protein-Tyrosine Kinases [antagonists & inhibitors]; 14. Randomized Controlled Trials as Topic; 15. Thrombocytopenia [etiology];
MESH terms:
Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease
1. *Cell‐ and Tissue‐Based Therapy; 2. Amyotrophic Lateral Sclerosis [complications, *therapy]; 3. Disease Progression; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Vital Capacity;
MESH terms:
Interventions for preventing falls in people with multiple sclerosis
1. Accidental Falls [*prevention & control]; 2. Accidents, Home [prevention & control]; 3. Exercise [*physiology]; 4. Exercise Therapy; 5. Multiple Sclerosis [*complications]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults
1. Brain Injuries, Traumatic [complications]; 2. Cardiovascular Agents [*therapeutic use]; 3. Indomethacin [*therapeutic use]; 4. Intracranial Hypertension [*drug therapy, etiology]; 5. Intracranial Pressure; 6. Randomized Controlled Trials as Topic;
MESH terms:
Exercise therapy for chronic fatigue syndrome
1. Cognitive Behavioral Therapy; 2. Depression [therapy]; 3. Exercise; 4. Exercise Therapy [adverse effects, *methods]; 5. Fatigue Syndrome, Chronic [psychology, *therapy]; 6. Health Status; 7. Patient Dropouts [statistics & numerical data]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Sleep Wake Disorders [therapy];
MESH terms:
Psychological therapies for the prevention of migraine in adults
1. Anxiety [therapy]; 2. Cognitive Behavioral Therapy; 3. Depression [therapy]; 4. Migraine Disorders [*prevention & control]; 5. Psychotherapy [*methods]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Mixed exercise training for adults with fibromyalgia
1. Biofeedback, Psychology; 2. Exercise Movement Techniques; 3. Exercise Therapy [*methods]; 4. Fatigue [etiology]; 5. Fibromyalgia [*therapy]; 6. Pain Management; 7. Quality of Life; 8. Randomized Controlled Trials as Topic;
MESH terms:
Non‐pharmacological interventions for chronic pain in multiple sclerosis
1. Chronic Pain [*therapy]; 2. Exercise Therapy [methods]; 3. Hydrotherapy; 4. Hypnosis; 5. Massage; 6. Multiple Sclerosis [*complications]; 7. Musculoskeletal Pain [*therapy]; 8. Neurofeedback; 9. Patient Education as Topic [methods]; 10. Psychotherapy; 11. Quality of Life; 12. Randomized Controlled Trials as Topic; 13. Relaxation Therapy; 14. Transcranial Direct Current Stimulation; 15. Transcutaneous Electric Nerve Stimulation [methods];
MESH terms:
Information provision for people with multiple sclerosis
1. *Patient Education as Topic; 2. Consumer Health Information; 3. Decision Making; 4. Health Knowledge, Attitudes, Practice; 5. Multiple Sclerosis [*therapy]; 6. Multiple Sclerosis, Relapsing‐Remitting [therapy]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic;
MESH terms:
Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
1. Adrenergic Uptake Inhibitors [*therapeutic use]; 2. Carnitine [therapeutic use]; 3. Cyclopropanes [*therapeutic use]; 4. Desvenlafaxine Succinate [*therapeutic use]; 5. Duloxetine Hydrochloride [*therapeutic use]; 6. Fibromyalgia [*drug therapy]; 7. Milnacipran; 8. Norepinephrine [*metabolism]; 9. Pregabalin [therapeutic use]; 10. Quality of Life; 11. Selective Serotonin Reuptake Inhibitors [*therapeutic use]; 12. Syndrome;
MESH terms:
Combination pharmacotherapy for the treatment of fibromyalgia in adults
1. 5-Hydroxytryptophan [therapeutic use]; 2. Acetaminophen [therapeutic use]; 3. Amitriptyline [therapeutic use]; 4. Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; 5. Antidepressive Agents [therapeutic use]; 6. Benzodiazepines [therapeutic use]; 7. Carisoprodol [therapeutic use]; 8. Drug Therapy, Combination [methods]; 9. Duloxetine Hydrochloride [therapeutic use]; 10. Fibromyalgia [*drug therapy]; 11. Fluoxetine [therapeutic use]; 12. Magnesium [therapeutic use]; 13. Malates [therapeutic use]; 14. Melatonin [therapeutic use]; 15. Monoamine Oxidase Inhibitors [therapeutic use]; 16. Muscle Relaxants, Central [therapeutic use]; 17. Pregabalin [therapeutic use]; 18. Randomized Controlled Trials as Topic;
MESH terms:
Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery
1. *Sutures; 2. *Wound Closure Techniques; 3. Carpal Tunnel Syndrome [*surgery]; 4. Cicatrix [psychology]; 5. Decompression, Surgical [methods]; 6. Inflammation [epidemiology, etiology]; 7. Pain Measurement; 8. Pain, Postoperative [diagnosis]; 9. Postoperative Complications [epidemiology, psychology]; 10. Randomized Controlled Trials as Topic; 11. Treatment Outcome;
MESH terms:
Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children
1. Administration, Inhalation; 2. Administration, Oral; 3. Administration, Rectal; 4. Anticonvulsants [administration & dosage, *therapeutic use]; 5. Diazepam [administration & dosage]; 6. Epilepsy, Tonic‐Clonic [*drug therapy]; 7. Injections, Intramuscular; 8. Injections, Intravenous; 9. Lorazepam [administration & dosage]; 10. Midazolam [administration & dosage]; 11. Randomized Controlled Trials as Topic; 12. Status Epilepticus [*drug therapy];
MESH terms:
Botulinum toxin for motor and phonic tics in Tourette's syndrome
1. Botulinum Toxins, Type A [adverse effects, *therapeutic use]; 2. Neuromuscular Agents [adverse effects, *therapeutic use]; 3. Tics [*drug therapy, etiology]; 4. Time Factors; 5. Tourette Syndrome [complications, *drug therapy];
MESH terms:
Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease
1. Amyotrophic Lateral Sclerosis [*complications]; 2. Benzhydryl Compounds [*therapeutic use]; 3. Breathing Exercises [*methods]; 4. Fatigue [etiology, *therapy]; 5. Modafinil; 6. Randomized Controlled Trials as Topic; 7. Resistance Training [*methods]; 8. Transcranial Magnetic Stimulation [*methods];
MESH terms:
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
1. Anti‐Inflammatory Agents [*therapeutic use]; 2. Dexamethasone [therapeutic use]; 3. Glucocorticoids [*therapeutic use]; 4. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating [*drug therapy]; 5. Prednisolone [therapeutic use]; 6. Prednisone [therapeutic use]; 7. Randomized Controlled Trials as Topic;
MESH terms:
alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
1. Adjuvants, Immunologic [*administration & dosage, adverse effects]; 2. Alemtuzumab [*administration & dosage, adverse effects]; 3. Disease Progression; 4. Drug Administration Schedule; 5. Interferon beta‐1a [*administration & dosage, adverse effects]; 6. Multiple Sclerosis, Relapsing‐Remitting [*drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Recurrence;
MESH terms:
Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease
1. *Quality of Life; 2. Amyotrophic Lateral Sclerosis [complications, *mortality]; 3. Disease Progression; 4. Motor Neuron Disease [mortality]; 5. Randomized Controlled Trials as Topic; 6. Respiration, Artificial [methods, *mortality]; 7. Respiratory Insufficiency [etiology, *mortality, therapy]; 8. Survival Analysis; 9. Time Factors;
MESH terms:
Whole body vibration exercise training for fibromyalgia
1. Combined Modality Therapy [methods]; 2. Exercise Therapy [*methods]; 3. Fatigue [diagnosis]; 4. Fibromyalgia [*therapy]; 5. Muscle Rigidity; 6. Pain Measurement; 7. Patient Dropouts [statistics & numerical data]; 8. Quality of Life; 9. Relaxation Therapy [*methods]; 10. Treatment Outcome; 11. Vibration [adverse effects, *therapeutic use];
MESH terms:
Zonisamide for essential tremor
1. Anticonvulsants [adverse effects, *therapeutic use]; 2. Essential Tremor [*drug therapy]; 3. Isoxazoles [adverse effects, *therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Zonisamide;
MESH terms:
Immunotherapy for diabetic amyotrophy
1. Diabetic Neuropathies [*drug therapy]; 2. Immunotherapy [*methods]; 3. Injections, Intravenous; 4. Methylprednisolone [*administration & dosage]; 5. Neuroprotective Agents [*administration & dosage];
MESH terms:
Aerobic exercise training for adults with fibromyalgia
1. *Exercise; 2. *Muscle Tonus; 3. *Quality of Life; 4. Fatigue [therapy]; 5. Fibromyalgia [physiopathology, *therapy]; 6. Pain Measurement; 7. Patient Dropouts [statistics & numerical data]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Drug therapy for chronic idiopathic axonal polyneuropathy
1. Axons; 2. Chronic Disease; 3. Gait Ataxia [drug therapy, etiology]; 4. Leg [*innervation]; 5. Polyneuropathies [*drug therapy];
MESH terms:
Tramadol for neuropathic pain in adults
1. Analgesics, Opioid [adverse effects, *therapeutic use]; 2. Neuralgia [*drug therapy, etiology]; 3. Randomized Controlled Trials as Topic; 4. Tramadol [adverse effects, *therapeutic use];
MESH terms:
Gabapentin for chronic neuropathic pain in adults
1. Amines [*administration & dosage, adverse effects]; 2. Analgesics [*administration & dosage, adverse effects]; 3. Chronic Disease; 4. Chronic Pain [*drug therapy]; 5. Cyclohexanecarboxylic Acids [*administration & dosage, adverse effects]; 6. Diabetic Neuropathies [drug therapy]; 7. Fibromyalgia [*drug therapy]; 8. Gabapentin; 9. Neuralgia [*drug therapy]; 10. Neuralgia, Postherpetic [drug therapy]; 11. Numbers Needed To Treat; 12. Randomized Controlled Trials as Topic; 13. gamma‐Aminobutyric Acid [*administration & dosage, adverse effects];
MESH terms:
Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy
1. Anticonvulsants [adverse effects, *therapeutic use]; 2. Dioxolanes [adverse effects, *therapeutic use]; 3. Epilepsies, Myoclonic [*drug therapy]; 4. Patient Dropouts [statistics & numerical data]; 5. Randomized Controlled Trials as Topic; 6. Seizures [drug therapy];
MESH terms:
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy
1. Anti‐Inflammatory Agents [therapeutic use]; 2. Azathioprine [therapeutic use]; 3. Immunoglobulins, Intravenous [therapeutic use]; 4. Immunologic Factors [*therapeutic use]; 5. Immunosuppressive Agents [*therapeutic use]; 6. Interferon beta‐1a [therapeutic use]; 7. Interferon‐beta [therapeutic use]; 8. Methotrexate [therapeutic use]; 9. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating [*drug therapy]; 10. Randomized Controlled Trials as Topic; 11. Treatment Outcome;
MESH terms:
Topiramate for essential tremor
1. Activities of Daily Living; 2. Anticonvulsants [adverse effects, *therapeutic use]; 3. Essential Tremor [*drug therapy]; 4. Fructose [adverse effects, *analogs & derivatives, therapeutic use]; 5. Patient Dropouts [statistics & numerical data]; 6. Publication Bias; 7. Randomized Controlled Trials as Topic; 8. Topiramate;
MESH terms:
Benzodiazepines for restless legs syndrome
1. Benzodiazepines [*therapeutic use]; 2. Restless Legs Syndrome [*drug therapy];
MESH terms:
Plasma exchange for Guillain‐Barré syndrome
1. *Plasma Exchange; 2. Guillain‐Barre Syndrome [immunology, *therapy]; 3. Muscle Strength; 4. Randomized Controlled Trials as Topic; 5. Recovery of Function; 6. Recurrence; 7. Treatment Outcome;
MESH terms:
Propofol versus thiopental sodium for the treatment of refractory status epilepticus
1. Anesthetics, Intravenous [*therapeutic use]; 2. Anticonvulsants [*therapeutic use]; 3. Drug Resistant Epilepsy [*drug therapy]; 4. Propofol [*therapeutic use]; 5. Respiration, Artificial; 6. Status Epilepticus [*drug therapy]; 7. Thiopental [*therapeutic use];
MESH terms:
Interventions to prevent and treat corticosteroid‐induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy
1. *Weight‐Bearing; 2. Adrenal Cortex Hormones [adverse effects]; 3. Bone Density [drug effects]; 4. Bone Density Conservation Agents [*therapeutic use]; 5. Calcium [therapeutic use]; 6. Diphosphonates [therapeutic use]; 7. Imidazoles [therapeutic use]; 8. Muscular Dystrophy, Duchenne [*drug therapy]; 9. Osteoporosis [chemically induced, complications, *drug therapy, prevention & control]; 10. Osteoporotic Fractures [etiology, *prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Risedronic Acid [therapeutic use]; 13. Spinal Fractures [etiology, *prevention & control]; 14. Vibration [*therapeutic use]; 15. Vitamin D [therapeutic use]; 16. Zoledronic Acid;
MESH terms:
Aspirin for acute treatment of episodic tension‐type headache in adults
1. Acetaminophen [therapeutic use]; 2. Administration, Oral; 3. Analgesics [administration & dosage, adverse effects, *therapeutic use]; 4. Aspirin [administration & dosage, adverse effects, *therapeutic use]; 5. Codeine [therapeutic use]; 6. Dipyrone [therapeutic use]; 7. Mentha piperita; 8. Pain Measurement; 9. Plant Oils [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Tension‐Type Headache [*drug therapy]; 12. Time Factors; 13. Treatment Outcome;
MESH terms:
Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease
1. Amyotrophic Lateral Sclerosis [*drug therapy, mortality]; 2. Baclofen [therapeutic use]; 3. Clinical Trials, Phase II as Topic; 4. Clinical Trials, Phase III as Topic; 5. GABA Agents [adverse effects, *therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Time Factors; 8. gamma‐Aminobutyric Acid [adverse effects, *therapeutic use];
MESH terms:
Progesterone for acute traumatic brain injury
1. Brain Injuries [*drug therapy, *mortality]; 2. Disability Evaluation; 3. Glasgow Coma Scale; 4. Injury Severity Score; 5. Intracranial Pressure [drug effects]; 6. Neuroprotective Agents [adverse effects, *therapeutic use]; 7. Progesterone [adverse effects, *therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Risk;
MESH terms:
Immediate‐release versus controlled‐release carbamazepine in the treatment of epilepsy
1. Anticonvulsants [adverse effects, *therapeutic use]; 2. Carbamazepine [adverse effects, *therapeutic use]; 3. Delayed‐Action Preparations [adverse effects, therapeutic use]; 4. Epilepsy [*drug therapy]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Antibiotics for the neurological complications of Lyme disease
1. Amoxicillin [therapeutic use]; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Borrelia burgdorferi; 4. Cefotaxime [therapeutic use]; 5. Ceftriaxone [therapeutic use]; 6. Doxycycline [therapeutic use]; 7. Lyme Disease [complications]; 8. Lyme Neuroborreliosis [*drug therapy]; 9. Penicillin G [therapeutic use]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Pregabalin for essential tremor
1. Anticonvulsants [administration & dosage, *therapeutic use]; 2. Essential Tremor [*drug therapy]; 3. Pregabalin [administration & dosage, *therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Upper Extremity;
MESH terms:
Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
1. Demyelinating Diseases [immunology, *therapy]; 2. Immunoglobulin M [blood, *immunology]; 3. Immunoglobulins, Intravenous [therapeutic use]; 4. Immunosuppressive Agents [therapeutic use]; 5. Immunotherapy [*methods]; 6. Myelin-Associated Glycoprotein [*immunology]; 7. Paraproteinemias [immunology, *therapy]; 8. Paraproteins [immunology]; 9. Peripheral Nervous System Diseases [immunology, *therapy]; 10. Plasma Exchange [methods]; 11. Randomized Controlled Trials as Topic; 12. Rituximab [therapeutic use];
MESH terms:
External drains versus no drains after burr‐hole evacuation for the treatment of chronic subdural haematoma in adults
1. Drainage [adverse effects, instrumentation, *methods, mortality]; 2. Dura Mater [surgery]; 3. Hematoma, Subdural, Chronic [*therapy]; 4. Osteotomy [methods]; 5. Randomized Controlled Trials as Topic; 6. Recurrence; 7. Secondary Prevention [instrumentation, methods]; 8. Skull [surgery];
MESH terms:
Pharmacological treatments for Friedreich ataxia
1. Antioxidants [adverse effects, *therapeutic use]; 2. Friedreich Ataxia [*drug therapy]; 3. Heart [drug effects]; 4. Hypertrophy, Left Ventricular [diagnostic imaging, drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Rare Diseases [drug therapy]; 7. Ubiquinone [adverse effects, *analogs & derivatives, therapeutic use]; 8. Ultrasonography; 9. Vitamin E [adverse effects, *therapeutic use];
MESH terms:
Corticosteroids for Bell's palsy (idiopathic facial paralysis)
1. Anti‐Inflammatory Agents [*therapeutic use]; 2. Bell Palsy [*drug therapy]; 3. Cortisone [*analogs & derivatives, therapeutic use]; 4. Glucocorticoids [adverse effects, *therapeutic use]; 5. Methylprednisolone [therapeutic use]; 6. Prednisolone [therapeutic use]; 7. Prednisone [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Recovery of Function; 10. Vitamins [therapeutic use];
MESH terms:
Cannabinoids for fibromyalgia
1. Amitriptyline [therapeutic use]; 2. Analgesics, Non-Narcotic [therapeutic use]; 3. Cannabinoids [adverse effects, *therapeutic use]; 4. Dronabinol [adverse effects, *analogs & derivatives, therapeutic use]; 5. Fibromyalgia [*drug therapy]; 6. Health Status; 7. *Quality of Life; 8. Randomized Controlled Trials as Topic;
MESH terms:
Opioids for restless legs syndrome
1. Analgesics, Opioid [adverse effects, *therapeutic use]; 2. Disorders of Excessive Somnolence [chemically induced]; 3. Naloxone [adverse effects, *therapeutic use]; 4. Oxycodone [adverse effects, *therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Restless Legs Syndrome [*drug therapy];
MESH terms:
Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults
1. Acetaminophen [adverse effects, *therapeutic use]; 2. Administration, Oral; 3. Analgesics, Non‐Narcotic [adverse effects, *therapeutic use]; 4. Pain Measurement; 5. Randomized Controlled Trials as Topic; 6. Tension‐Type Headache [diagnosis, *drug therapy]; 7. Time Factors;
MESH terms:
Antipsychotics for fibromyalgia in adults
1. Amitriptyline [therapeutic use]; 2. Analgesics, Non‐Narcotic [therapeutic use]; 3. Antipsychotic Agents [*therapeutic use]; 4. Fibromyalgia [*drug therapy]; 5. Quetiapine Fumarate [*therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Sleep Wake Disorders [drug therapy];
MESH terms:
Pharmacological treatment for Kleine‐Levin syndrome
1. Kleine‐Levin Syndrome [*drug therapy]; 2. Rare Diseases [*drug therapy];
MESH terms:
Corticosteroids for the treatment of Duchenne muscular dystrophy
1. Adrenal Cortex Hormones [administration & dosage, adverse effects, *therapeutic use]; 2. Glucocorticoids [administration & dosage, adverse effects, *therapeutic use]; 3. Muscle Strength [*drug effects]; 4. Muscular Dystrophy, Duchenne [*drug therapy]; 5. Prednisolone [therapeutic use]; 6. Prednisone [therapeutic use]; 7. Pregnenediones [administration & dosage, therapeutic use]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Walking;
MESH terms:
Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis
1. Anticonvulsants [*therapeutic use]; 2. Intracranial Thrombosis [*complications]; 3. Primary Prevention; 4. Secondary Prevention; 5. Seizures [*etiology, prevention & control]; 6. Venous Thrombosis [*complications];
MESH terms:
Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults
1. Acute Disease; 2. Anti-Inflammatory Agents, Non-Steroidal [*therapeutic use]; 3. Drug Combinations; 4. Drug Therapy, Combination [methods]; 5. Migraine Disorders [*drug therapy]; 6. Naproxen [*therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Serotonin 5-HT1 Receptor Agonists [*therapeutic use]; 9. Sumatriptan [*administration & dosage];
MESH terms:
Drugs for the acute treatment of migraine in children and adolescents
1. Acetaminophen [therapeutic use]; 2. Analgesics, Non-Narcotic [*therapeutic use]; 3. Dihydroergotamine [therapeutic use]; 4. Ibuprofen [therapeutic use]; 5. Migraine Disorders [*drug therapy]; 6. Serotonin Receptor Agonists [adverse effects, *therapeutic use]; 7. Time Factors; 8. Tryptamines [*therapeutic use];
MESH terms:
Fingolimod for relapsing‐remitting multiple sclerosis
1. Fingolimod Hydrochloride [adverse effects, *therapeutic use]; 2. Immunosuppressive Agents [adverse effects, *therapeutic use]; 3. Interferon‐beta [therapeutic use]; 4. Multiple Sclerosis, Relapsing‐Remitting [*drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Time Factors;
MESH terms:
Posture and fluids for preventing post‐dural puncture headache
1. *Bed Rest; 2. *Early Ambulation; 3. Fluid Therapy [*methods]; 4. Head; 5. Patient Positioning [*methods]; 6. Post-Dural Puncture Headache [*prevention & control]; 7. *Posture; 8. Spinal Puncture [adverse effects];
MESH terms:
Interventions for psychotic symptoms concomitant with epilepsy
1. Antipsychotic Agents [*therapeutic use]; 2. Benzodiazepines [*therapeutic use]; 3. Epilepsy [*psychology]; 4. Olanzapine; 5. Psychotic Disorders [*drug therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Alprazolam for essential tremor
1. Alprazolam [adverse effects, *therapeutic use]; 2. Anticonvulsants [adverse effects, *therapeutic use]; 3. Constipation [chemically induced]; 4. Essential Tremor [*drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Xerostomia [chemically induced];
MESH terms:
Vigabatrin versus carbamazepine monotherapy for epilepsy
1. Anticonvulsants [adverse effects, *therapeutic use]; 2. Carbamazepine [adverse effects, *therapeutic use]; 3. Epilepsy [*drug therapy]; 4. Randomized Controlled Trials as Topic; 5. Risk Assessment; 6. Vigabatrin [adverse effects, *therapeutic use];
MESH terms:
Routine intracranial pressure monitoring in acute coma
1. *Cerebrovascular Circulation; 2. Acute Disease; 3. Brain Injuries [complications]; 4. Coma [*physiopathology]; 5. Intracranial Hypertension [*physiopathology]; 6. Intracranial Pressure [physiology]; 7. Monitoring, Physiologic [methods];
MESH terms:
Psychological therapies for the management of chronic neuropathic pain in adults
1. Chronic Pain [*therapy]; 2. *Cognitive Behavioral Therapy; 3. Neuralgia [*therapy]; 4. *Psychotherapy, Group; 5. Randomized Controlled Trials as Topic;
MESH terms:
Sodium channel blockers for neuroprotection in multiple sclerosis
1. Disease Progression; 2. Immunosuppressive Agents [therapeutic use]; 3. Lamotrigine; 4. Multiple Sclerosis [drug therapy]; 5. Multiple Sclerosis, Chronic Progressive [*drug therapy]; 6. Neuroprotection; 7. Randomized Controlled Trials as Topic; 8. Sodium Channel Blockers [adverse effects, *therapeutic use]; 9. Triazines [adverse effects, *therapeutic use];
MESH terms:
Milnacipran for pain in fibromyalgia in adults
1. Analgesics [*administration & dosage, adverse effects]; 2. Chronic Disease; 3. Cyclopropanes [*administration & dosage, adverse effects]; 4. Fibromyalgia [*drug therapy]; 5. Milnacipran; 6. Neuralgia [*drug therapy]; 7. Selective Serotonin Reuptake Inhibitors [*administration & dosage, adverse effects];
MESH terms:
Interventions for fatigue in Parkinson's disease
1. *Exercise; 2. Central Nervous System Stimulants [*therapeutic use]; 3. Dopamine Agents [*therapeutic use]; 4. Fatigue [etiology, *therapy]; 5. Parkinson Disease [*complications]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Oral nonsteroidal anti‐inflammatory drugs for neuropathic pain
1. Administration, Oral; 2. Anti-Inflammatory Agents, Non-Steroidal [*administration & dosage]; 3. Back Pain [drug therapy]; 4. Celecoxib [therapeutic use]; 5. Neuralgia [*drug therapy]; 6. Neuralgia, Postherpetic [drug therapy]; 7. Pregabalin [therapeutic use]; 8. Pyrazoles [therapeutic use]; 9. Pyridazines [therapeutic use]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Surgery for scoliosis in Duchenne muscular dystrophy
1. Muscular Dystrophy, Duchenne [*complications]; 2. Scoliosis [complications, *surgery]; 3. Spine [surgery];
MESH terms:
Buprenorphine for neuropathic pain in adults
1. Analgesics, Opioid [*therapeutic use]; 2. Buprenorphine [*therapeutic use]; 3. Neuralgia [*drug therapy];
MESH terms:
Exercise therapy for fatigue in multiple sclerosis
1. Exercise Therapy [*methods]; 2. Fatigue [etiology, *therapy]; 3. Multiple Sclerosis [*complications, *rehabilitation]; 4. Physical Conditioning, Human [*methods]; 5. Physical Endurance; 6. Randomized Controlled Trials as Topic; 7. Resistance Training; 8. Yoga;
MESH terms:
Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy
1. *Plasma Exchange; 2. Cross‐Over Studies; 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating [*therapy]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Venlafaxine for neuropathic pain in adults
1. Analgesics, Non‐Narcotic [adverse effects, *therapeutic use]; 2. Antidepressive Agents, Second‐Generation [adverse effects, *therapeutic use]; 3. Carbamazepine [therapeutic use]; 4. Imipramine [therapeutic use]; 5. Neuralgia [*drug therapy]; 6. Off‐Label Use; 7. Patient Dropouts; 8. Randomized Controlled Trials as Topic; 9. Venlafaxine Hydrochloride [adverse effects, *therapeutic use];
MESH terms:
Pharmacological treatments for preventing epilepsy following traumatic head injury
1. Anticonvulsants [*therapeutic use]; 2. Carbamazepine [therapeutic use]; 3. Cause of Death; 4. Craniocerebral Trauma [*complications, mortality]; 5. Epilepsy [etiology, mortality, *prevention & control]; 6. Levetiracetam; 7. Magnesium Sulfate [therapeutic use]; 8. Neuroprotective Agents [*therapeutic use]; 9. Phenytoin [therapeutic use]; 10. Piracetam [analogs & derivatives, therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Valproic Acid [therapeutic use];
MESH terms:
Ibuprofen for acute treatment of episodic tension‐type headache in adults
1. Acetaminophen; 2. Administration, Oral; 3. Analgesics, Non‐Narcotic [*administration & dosage, adverse effects]; 4. Cyclooxygenase Inhibitors [therapeutic use]; 5. Diclofenac [administration & dosage]; 6. Ibuprofen [*administration & dosage, adverse effects]; 7. Ketoprofen [administration & dosage]; 8. Naproxen [administration & dosage]; 9. Numbers Needed To Treat; 10. Pain Measurement; 11. Piroxicam [administration & dosage]; 12. Randomized Controlled Trials as Topic; 13. Tension‐Type Headache [*drug therapy]; 14. Time Factors;
MESH terms:
Neuropsychological and psychological interventions for people with newly diagnosed epilepsy
1. *Practice Patterns, Nurses'; 2. Anxiety [nursing, *therapy]; 3. Cognitive Behavioral Therapy [*methods]; 4. Depression [nursing, *therapy]; 5. Epilepsy [diagnosis, *psychology]; 6. Memory Disorders [therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Drug therapy for treating post‐dural puncture headache
1. Adrenocorticotropic Hormone [therapeutic use]; 2. Amines [therapeutic use]; 3. Analgesics [*therapeutic use]; 4. Blood Patch, Epidural [methods]; 5. Caffeine [therapeutic use]; 6. Cyclohexanecarboxylic Acids [therapeutic use]; 7. Gabapentin; 8. gamma-Aminobutyric Acid [therapeutic use]; 9. Hydrocortisone [therapeutic use]; 10. Pain Measurement [methods]; 11. Post-Dural Puncture Headache [*drug therapy]; 12. Randomized Controlled Trials as Topic; 13. Spinal Puncture [*adverse effects]; 14. Sumatriptan [therapeutic use]; 15. Theophylline [therapeutic use]; 16. Treatment Outcome;
MESH terms:
Amitriptyline for neuropathic pain in adults
1. Amitriptyline [adverse effects, *therapeutic use]; 2. Analgesics, Non‐Narcotic [adverse effects, *therapeutic use]; 3. Antidepressive Agents, Tricyclic [adverse effects, therapeutic use]; 4. Neuralgia [*drug therapy, etiology]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Milnacipran for neuropathic pain in adults
1. Analgesics [*administration & dosage, adverse effects]; 2. Back Pain [*drug therapy]; 3. Chronic Pain [*drug therapy]; 4. Cyclopropanes [*administration & dosage, adverse effects]; 5. Fibromyalgia [drug therapy]; 6. Milnacipran; 7. Neuralgia [*drug therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Selective serotonin reuptake inhibitors for fibromyalgia syndrome
1. Amitriptyline [therapeutic use]; 2. Citalopram [therapeutic use]; 3. Fibromyalgia [*drug therapy]; 4. Fluoxetine [therapeutic use]; 5. Melatonin [therapeutic use]; 6. Musculoskeletal Pain [drug therapy, etiology]; 7. Paroxetine [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Selective Serotonin Reuptake Inhibitors [*therapeutic use]; 10. Syndrome;
MESH terms:
Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension‐type headache in adults
1. Adrenergic Uptake Inhibitors [*therapeutic use]; 2. Citalopram [therapeutic use]; 3. Cyclohexanols [therapeutic use]; 4. Fluoxetine [therapeutic use]; 5. Fluvoxamine [therapeutic use]; 6. Norepinephrine [*metabolism]; 7. Paroxetine [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Sertraline [therapeutic use]; 10. Tension‐Type Headache [*prevention & control]; 11. Venlafaxine Hydrochloride;
MESH terms:
Dimethyl fumarate for multiple sclerosis
1. Administration, Oral; 2. Dimethyl Fumarate; 3. Drug Administration Schedule; 4. Fumarates [*administration & dosage, adverse effects]; 5. Immunosuppressive Agents [*administration & dosage, adverse effects]; 6. Multiple Sclerosis, Relapsing‐Remitting [*drug therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Telerehabilitation for persons with multiple sclerosis
1. *Telemedicine; 2. Multiple Sclerosis [*rehabilitation]; 3. Randomized Controlled Trials as Topic; 4. Treatment Outcome;
MESH terms:
Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults
1. Amitriptyline [therapeutic use]; 2. Citalopram [therapeutic use]; 3. Migraine Disorders [drug therapy, *prevention & control]; 4. Randomized Controlled Trials as Topic; 5. Selective Serotonin Reuptake Inhibitors [*therapeutic use]; 6. Serotonin and Noradrenaline Reuptake Inhibitors [*therapeutic use]; 7. Venlafaxine Hydrochloride [therapeutic use];
MESH terms:
Treatment for IgG and IgA paraproteinaemic neuropathy
1. *Immunoglobulin A; 2. *Immunoglobulin G; 3. *Plasma Exchange; 4. Monoclonal Gammopathy of Undetermined Significance [*therapy]; 5. Peripheral Nervous System Diseases [*therapy]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy
1. Drug Therapy, Combination; 2. Immunoglobulins, Intravenous [*therapeutic use]; 3. Immunologic Factors [*therapeutic use]; 4. Immunosuppressive Agents [*therapeutic use]; 5. Motor Neuron Disease [*drug therapy]; 6. Muscle Strength [drug effects]; 7. Mycophenolic Acid [*analogs & derivatives, therapeutic use]; 8. Polyneuropathies [*drug therapy]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Physical rehabilitation for critical illness myopathy and neuropathy
1. *Activities of Daily Living; 2. Critical Illness; 3. Muscular Diseases [*rehabilitation]; 4. Polyneuropathies [*rehabilitation]; 5. Quality of Life;
MESH terms:
Early versus late antiepileptic drug withdrawal for people with epilepsy in remission
1. *Withholding Treatment; 2. Anticonvulsants [*administration & dosage]; 3. Confidence Intervals; 4. Epilepsies, Partial [*drug therapy]; 5. Epilepsy, Absence [*drug therapy]; 6. Epilepsy, Generalized [*drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Recurrence; 9. Remission Induction; 10. Risk; 11. Risk Assessment; 12. Time Factors;
MESH terms:
Interventions for fatigue in peripheral neuropathy
1. Amantadine [adverse effects, *therapeutic use]; 2. Ascorbic Acid [adverse effects, *therapeutic use]; 3. Charcot‐Marie‐Tooth Disease [*complications]; 4. Fatigue [etiology, *therapy]; 5. Guillain‐Barre Syndrome [*complications]; 6. Peripheral Nervous System Diseases [complications]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Non‐pharmacological interventions for chronic pain in people with spinal cord injury
1. Acupuncture Therapy [methods]; 2. Anxiety [therapy]; 3. Chronic Pain [psychology, *therapy]; 4. Cognitive Behavioral Therapy [methods]; 5. Depression [therapy]; 6. Electric Stimulation Therapy [methods]; 7. Exercise Therapy [methods]; 8. Hypnosis [methods]; 9. Neuralgia [psychology, *therapy]; 10. Nociceptive Pain [psychology, *therapy]; 11. Pain Management [*methods]; 12. Pain Measurement [methods]; 13. Quality of Life; 14. Randomized Controlled Trials as Topic; 15. Reproducibility of Results; 16. Shoulder Pain [therapy]; 17. Spinal Cord Injuries [*complications]; 18. Transcranial Magnetic Stimulation [methods]; 19. Transcutaneous Electric Nerve Stimulation [methods];
MESH terms:
Aquatic exercise training for fibromyalgia
1. Exercise Therapy [adverse effects, *methods]; 2. Fibromyalgia [*therapy]; 3. Hydrotherapy [adverse effects, *methods]; 4. Muscle Strength; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome;
MESH terms:
Pharmacotherapy for sleep bruxism
1. Amitriptyline [therapeutic use]; 2. Bromocriptine [therapeutic use]; 3. Clonidine [therapeutic use]; 4. Levodopa [therapeutic use]; 5. Propranolol [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Sleep Bruxism [*drug therapy]; 8. Tryptophan [therapeutic use];
MESH terms:
Acetylcholinesterase inhibitor treatment for myasthenia gravis
1. Administration, Intranasal; 2. Cholinesterase Inhibitors [administration & dosage, *therapeutic use]; 3. Myasthenia Gravis [*drug therapy]; 4. Neostigmine [administration & dosage, *therapeutic use]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Intravenous immunoglobulin for Guillain‐Barré syndrome
1. Guillain-Barre Syndrome [immunology, *therapy]; 2. Immunoglobulins, Intravenous [adverse effects, *therapeutic use]; 3. Outcome Assessment, Health Care; 4. Plasma Exchange [adverse effects]; 5. Randomized Controlled Trials as Topic; 6. Recovery of Function;
MESH terms:
Anticonvulsant therapy for status epilepticus
1. Anticonvulsants [*therapeutic use]; 2. Diazepam [therapeutic use]; 3. Injections, Intravenous; 4. Lorazepam [therapeutic use]; 5. Midazolam [therapeutic use]; 6. Phenobarbital [therapeutic use]; 7. Phenytoin [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Status Epilepticus [*drug therapy];
MESH terms:
Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes
1. *Watchful Waiting; 2. Anticonvulsants [*therapeutic use]; 3. Benzodiazepines [therapeutic use]; 4. Carbamazepine [analogs & derivatives, therapeutic use]; 5. Clobazam; 6. Epilepsy [*drug therapy, physiopathology]; 7. Fructose [analogs & derivatives, therapeutic use]; 8. Induction Chemotherapy [methods]; 9. Levetiracetam; 10. Oxcarbazepine; 11. Piracetam [analogs & derivatives, therapeutic use]; 12. Placebos; 13. Randomized Controlled Trials as Topic; 14. Thiazines [therapeutic use]; 15. Topiramate;
MESH terms:
Physiotherapy for Parkinson's disease: a comparison of techniques
1. *Physical Therapy Modalities; 2. Gait [physiology]; 3. Parkinson Disease [*rehabilitation]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Zolmitriptan for acute migraine attacks in adults
1. Acute Pain [*drug therapy]; 2. Administration, Oral; 3. Migraine Disorders [*drug therapy]; 4. Oxazolidinones [adverse effects, *therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Serotonin 5‐HT1 Receptor Agonists [adverse effects, *therapeutic use]; 7. Time Factors; 8. Tryptamines [adverse effects, *therapeutic use];
MESH terms:
Carbamazepine for chronic neuropathic pain and fibromyalgia in adults
1. Analgesics, Non‐Narcotic [adverse effects, *therapeutic use]; 2. Carbamazepine [adverse effects, *therapeutic use]; 3. Chronic Pain [*drug therapy, etiology]; 4. Diabetic Neuropathies [*drug therapy]; 5. Fibromyalgia [*drug therapy]; 6. Neuralgia [drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Stroke [complications]; 9. Trigeminal Neuralgia [*drug therapy];
MESH terms:
Mycophenolate mofetil for relapsing‐remitting multiple sclerosis
1. Adjuvants, Immunologic [therapeutic use]; 2. Immunosuppressive Agents [adverse effects, *therapeutic use]; 3. Interferon beta‐1a; 4. Interferon‐beta [therapeutic use]; 5. Multiple Sclerosis, Relapsing‐Remitting [*drug therapy]; 6. Mycophenolic Acid [adverse effects, *analogs & derivatives, therapeutic use]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Antiviral treatment for preventing postherpetic neuralgia
1. 2‐Aminopurine [*analogs & derivatives, therapeutic use]; 2. Acyclovir [*therapeutic use]; 3. Antiviral Agents [*therapeutic use]; 4. Famciclovir; 5. Neuralgia, Postherpetic [*prevention & control]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for preventing critical illness polyneuropathy and critical illness myopathy
1. Adrenal Cortex Hormones [therapeutic use]; 2. Critical Care; 3. Critical Illness; 4. Electric Stimulation Therapy [methods]; 5. Human Growth Hormone [therapeutic use]; 6. Hypoglycemia [chemically induced]; 7. Hypoglycemic Agents [adverse effects, therapeutic use]; 8. Insulin [adverse effects, therapeutic use]; 9. Length of Stay [statistics & numerical data]; 10. Muscular Diseases [mortality, *prevention & control]; 11. Physical Therapy Modalities; 12. Polyneuropathies [mortality, *prevention & control]; 13. Randomized Controlled Trials as Topic; 14. Recombinant Proteins [therapeutic use]; 15. Respiration, Artificial [statistics & numerical data];
MESH terms:
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
1. Analgesics [*administration & dosage, adverse effects]; 2. Chronic Pain [*drug therapy]; 3. Diabetic Neuropathies [*drug therapy]; 4. Duloxetine Hydrochloride; 5. Fibromyalgia [*drug therapy]; 6. Neuralgia [*drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Thiophenes [*administration & dosage, adverse effects];
MESH terms:
Immunotherapy for idiopathic lumbosacral plexopathy
1. *Lumbosacral Plexus; 2. Immunotherapy [*methods]; 3. Peripheral Nervous System Diseases [*therapy];
MESH terms:
Mechanical insufflation‐exsufflation for people with neuromuscular disorders
1. Cough [*physiopathology]; 2. Insufflation [adverse effects, *methods]; 3. Lung [*metabolism]; 4. Neuromuscular Diseases [*complications]; 5. Randomized Controlled Trials as Topic; 6. Respiratory Insufficiency [physiopathology, *therapy]; 7. Suction [methods];
MESH terms:
Passive movements for the treatment and prevention of contractures
1. Ankle Joint; 2. Contracture [prevention & control, *therapy]; 3. Manipulation, Orthopedic [*methods]; 4. Muscle Spasticity [therapy]; 5. Pain Measurement; 6. Randomized Controlled Trials as Topic; 7. Range of Motion, Articular;
MESH terms:
Daclizumab for relapsing remitting multiple sclerosis
1. Antibodies, Monoclonal, Humanized [*therapeutic use]; 2. Daclizumab; 3. Immunoglobulin G [*therapeutic use]; 4. Immunosuppressive Agents [*therapeutic use]; 5. Interferon‐beta [therapeutic use]; 6. Multiple Sclerosis, Relapsing‐Remitting [*drug therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Pharmacological treatment for memory disorder in multiple sclerosis
1. Donepezil; 2. Ginkgo biloba; 3. Indans [therapeutic use]; 4. Memantine [therapeutic use]; 5. Memory Disorders [*drug therapy, etiology]; 6. Multiple Sclerosis [*complications]; 7. Neuroprotective Agents [therapeutic use]; 8. Nootropic Agents [therapeutic use]; 9. Phenylcarbamates [therapeutic use]; 10. Phytotherapy [methods]; 11. Piperidines [therapeutic use]; 12. Randomized Controlled Trials as Topic; 13. Rivastigmine;
MESH terms:
Rituximab for relapsing‐remitting multiple sclerosis
1. Antibodies, Monoclonal, Murine‐Derived [*therapeutic use]; 2. Immunologic Factors [*therapeutic use]; 3. Multiple Sclerosis, Relapsing‐Remitting [*drug therapy]; 4. Randomized Controlled Trials as Topic; 5. Rituximab;
MESH terms:
Non‐antiepileptic drugs for trigeminal neuralgia
1. Amitriptyline [therapeutic use]; 2. Analgesics [*therapeutic use]; 3. Anticonvulsants [*therapeutic use]; 4. Baclofen [therapeutic use]; 5. Carbamazepine [therapeutic use]; 6. Clomipramine [therapeutic use]; 7. Clonidine [analogs & derivatives, therapeutic use]; 8. Pimozide [therapeutic use]; 9. Propoxycaine [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Tocainide [therapeutic use]; 12. Trigeminal Neuralgia [*drug therapy];
MESH terms:
Lamotrigine for chronic neuropathic pain and fibromyalgia in adults
1. Acute Disease; 2. Analgesics [*therapeutic use]; 3. Anticonvulsants [therapeutic use]; 4. Chronic Disease; 5. Fibromyalgia [*drug therapy]; 6. Lamotrigine; 7. Neuralgia [*drug therapy]; 8. Randomized Controlled Trials as Topic; 9. Triazines [*therapeutic use];
MESH terms:
Naproxen with or without an antiemetic for acute migraine headaches in adults
1. Anti-Inflammatory Agents, Non-Steroidal [*administration & dosage, adverse effects]; 2. Antiemetics [*administration & dosage]; 3. Drug Therapy, Combination [methods]; 4. Migraine Disorders [complications, *drug therapy]; 5. Naproxen [*administration & dosage, adverse effects]; 6. Nausea [complications, *drug therapy]; 7. Piperidines [administration & dosage]; 8. Randomized Controlled Trials as Topic; 9. Sumatriptan [administration & dosage]; 10. Tryptamines [administration & dosage]; 11. Vomiting [complications, *drug therapy];
MESH terms:
Thymectomy for non‐thymomatous myasthenia gravis
1. *Thymectomy; 2. Myasthenia Gravis [etiology, *surgery];